Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome
PURPOSE: Brahma (BRM) is a critical catalytic subunit of the SWI/SNF chromatin remodeling complex; expression of BRM is commonly lost in various cancer types. BRM promoter polymorphisms (BRM-741; BRM-1321) are associated with loss of BRM expression, and with cancer risk/survival. We evaluated these two polymorphisms in the overall survival (OS) of esophageal adenocarcinoma (EAC) patients.
RESULTS: Of 270 patients, 37% were stage IV. Minor allele frequencies were 47-49%; 15% were double-homozygotes. When compared to the wild-type genotype, the homozygous variant of BRM-741 carried an adjusted OS hazard ratio (aHR) of 1.64 (95% CI:1.1-2.4); for BRM-1321, the aHR was 2.09 (95% CI:1.4-3.0). Compared to the double wild-type, carrying homozygous variants of both promoter polymorphisms (double-homozygote) yielded an aHR of 2.21 (95% CI:1.4-3.6). Directions/magnitudes of associations were similar in subsets by age, gender, smoking status, use of platinum agents, and disease stage, and for progression-free survival.
MATERIALS AND METHODS: In a cohort of EAC patients of all stages (84% male; median age of 64 years), two BRM polymorphisms were genotyped. Cox proportional hazards models, adjusted for known prognostic variables, estimated the association of polymorphisms with OS.
CONCLUSIONS: BRM polymorphisms were associated with OS in EAC in this study. Validation studies are warranted.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Oncotarget - 8(2017), 17 vom: 25. Apr., Seite 28093-28100 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Korpanty, Grzegorz J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Brahma |
|---|
| Anmerkungen: |
Date Completed 05.03.2018 Date Revised 13.11.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.18632/oncotarget.15890 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM271137665 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM271137665 | ||
| 003 | DE-627 | ||
| 005 | 20231224232047.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/oncotarget.15890 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0903.xml |
| 035 | |a (DE-627)NLM271137665 | ||
| 035 | |a (NLM)28427211 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Korpanty, Grzegorz J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.03.2018 | ||
| 500 | |a Date Revised 13.11.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: Brahma (BRM) is a critical catalytic subunit of the SWI/SNF chromatin remodeling complex; expression of BRM is commonly lost in various cancer types. BRM promoter polymorphisms (BRM-741; BRM-1321) are associated with loss of BRM expression, and with cancer risk/survival. We evaluated these two polymorphisms in the overall survival (OS) of esophageal adenocarcinoma (EAC) patients | ||
| 520 | |a RESULTS: Of 270 patients, 37% were stage IV. Minor allele frequencies were 47-49%; 15% were double-homozygotes. When compared to the wild-type genotype, the homozygous variant of BRM-741 carried an adjusted OS hazard ratio (aHR) of 1.64 (95% CI:1.1-2.4); for BRM-1321, the aHR was 2.09 (95% CI:1.4-3.0). Compared to the double wild-type, carrying homozygous variants of both promoter polymorphisms (double-homozygote) yielded an aHR of 2.21 (95% CI:1.4-3.6). Directions/magnitudes of associations were similar in subsets by age, gender, smoking status, use of platinum agents, and disease stage, and for progression-free survival | ||
| 520 | |a MATERIALS AND METHODS: In a cohort of EAC patients of all stages (84% male; median age of 64 years), two BRM polymorphisms were genotyped. Cox proportional hazards models, adjusted for known prognostic variables, estimated the association of polymorphisms with OS | ||
| 520 | |a CONCLUSIONS: BRM polymorphisms were associated with OS in EAC in this study. Validation studies are warranted | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a brahma | |
| 650 | 4 | |a cancer prognosis | |
| 650 | 4 | |a chromatin remodeling | |
| 650 | 4 | |a esophageal cancer | |
| 650 | 4 | |a polymorphism | |
| 650 | 7 | |a SMARCA2 protein, human |2 NLM | |
| 650 | 7 | |a Transcription Factors |2 NLM | |
| 700 | 1 | |a Eng, Lawson |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Faluyi, Olusola Olusesan |e verfasserin |4 aut | |
| 700 | 1 | |a Renouf, Daniel J |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Dangxiao |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Devalben |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Zhuo |e verfasserin |4 aut | |
| 700 | 1 | |a Tse, Brandon C |e verfasserin |4 aut | |
| 700 | 1 | |a Knox, Jennifer J |e verfasserin |4 aut | |
| 700 | 1 | |a Dodbiba, Lorin |e verfasserin |4 aut | |
| 700 | 1 | |a Teichman, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Azad, Abul Kalam |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Darling, Gail |e verfasserin |4 aut | |
| 700 | 1 | |a Reisman, David |e verfasserin |4 aut | |
| 700 | 1 | |a Cuffe, Sinead |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Geoffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Wei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncotarget |d 2010 |g 8(2017), 17 vom: 25. Apr., Seite 28093-28100 |w (DE-627)NLM199620113 |x 1949-2553 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2017 |g number:17 |g day:25 |g month:04 |g pages:28093-28100 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/oncotarget.15890 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2017 |e 17 |b 25 |c 04 |h 28093-28100 | ||